Literature DB >> 28911144

Randomized Trial Comparing Two Algorithms for Levothyroxine Dose Adjustment in Pregnant Women With Primary Hypothyroidism.

Shannon D Sullivan1,2, Erin Downs2, Geanina Popoveniuc2, Alexander Zeymo3, Jacqueline Jonklaas4, Kenneth D Burman2.   

Abstract

Context: Regulation of maternal thyroid hormones during pregnancy is crucial for optimal maternal and fetal outcomes. There are no specific guidelines addressing maternal levothyroxine (LT4) dose adjustments throughout pregnancy. Objective: To compare two LT4 dose-adjustment algorithms in hypothyroid pregnant women. Design: Thirty-three women on stable LT4 doses were recruited at <10 weeks gestation during 38 pregnancies and randomized to one of two dose-adjustment groups. Group 1 (G1) used an empiric two-pill/week dose increase followed by subsequent pill-per-week dose adjustments. In group 2 (G2), LT4 dose was adjusted in an ongoing approach in micrograms per day based on current thyroid stimulating hormone (TSH) level and LT4 dose. TSH was monitored every 2 weeks in trimesters 1 and 2 and every 4 weeks in trimester 3. Setting: Academic endocrinology clinics in Washington, DC. Main Outcome Measure: Proportion of TSH values within trimester-specific goal ranges.
Results: Mean gestational age at study entry was 6.4 ± 2.1 weeks. Seventy-five percent of TSH values were within trimester-specific goal ranges in G1 compared with 81% in G2 (P = 0.09). Similar numbers of LT4 dose adjustments per pregnancy were required in both groups (G1, 3.1 ± 2.0 vs G2, 4.1 ± 3.2; P = 0.27). Women in G1 were more likely to have suppressed TSH <0.1 mIU/L in trimester 1 (P = 0.01). Etiology of hypothyroidism, but not thyroid antibody status, was associated with proportion of goal TSH values. Conclusions: We compared two options for LT4 dose adjustment and showed that an ongoing adjustment approach is as effective as empiric dose increase for maintaining goal TSH in hypothyroid women during pregnancy.
Copyright © 2017 Endocrine Society

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28911144     DOI: 10.1210/jc.2017-01086

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

Review 1.  Thyroid hormone therapy of hypothyroidism in pregnancy.

Authors:  Zhongyan Shan; Weiping Teng
Journal:  Endocrine       Date:  2019-10-15       Impact factor: 3.633

Review 2.  Recent Advances in Treatment of Recurrent Spontaneous Abortion.

Authors:  Tianqing Deng; Xiaoyang Liao; Shaomi Zhu
Journal:  Obstet Gynecol Surv       Date:  2022-06       Impact factor: 3.015

Review 3.  Subclinical Hypothyroidism in Women Planning Conception and During Pregnancy: Who Should Be Treated and How?

Authors:  Spyridoula Maraka; Naykky M Singh Ospina; George Mastorakos; Derek T O'Keeffe
Journal:  J Endocr Soc       Date:  2018-05-03

Review 4.  Levothyroxine Dose Adjustment to Optimise Therapy Throughout a Patient's Lifetime.

Authors:  Leonidas H Duntas; Jacqueline Jonklaas
Journal:  Adv Ther       Date:  2019-09-04       Impact factor: 3.845

5.  Effect of Bisphenol A-Mediated RBP-4 on Pregnancy Outcomes in Nonobese Pregnant Female with Subclinical Hypothyroidism.

Authors:  Danyan Chen; Hongman Wang; Xi Chen; Li Li; Liwei Luo; Rongxi Huang
Journal:  Contrast Media Mol Imaging       Date:  2022-07-20       Impact factor: 3.009

Review 6.  Preconception Counseling in Patients with Hypothyroidism and/or Thyroid Autoimmunity.

Authors:  Mihaela Țarnă; Luminița Nicoleta Cima; Anca Maria Panaitescu; Carmen Sorina Martin; Anca Elena Sîrbu; Carmen Gabriela Barbu; Bogdan Pavel; Andreea Nicoleta Șerbănică; Simona Fica
Journal:  Medicina (Kaunas)       Date:  2022-08-18       Impact factor: 2.948

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.